Biowaiver monographs for immediate release solid oral dosage forms: prednisolone

Area of Science:

• Pharmaceutical Sciences
• Pharmacokinetics
• Drug Formulation

Background:

• Immediate-release (IR) solid oral dosage forms require bioequivalence (BE) testing for approval.
• Waivers for in vivo BE testing can streamline drug approval processes.
• Prednisolone is a widely used corticosteroid with established therapeutic indications.

Purpose of the Study:

• To review literature data supporting a waiver of in vivo bioequivalence testing for IR solid oral dosage forms of prednisolone.
• To assess the safety implications of granting such a biowaiver.
• To identify conditions under which a biowaiver for prednisolone formulations would be acceptable.

Main Methods:

• Literature review of prednisolone's solubility, absorption, and permeability data.
• Analysis of prednisolone's pharmacokinetic properties and therapeutic index.
• Evaluation of potential excipient interactions in oral dosage forms.

Main Results:

• Prednisolone's physicochemical properties suggest a Biopharmaceutics Classification System (BCS) Class 1 classification.
• Available data indicate that prednisolone has a favorable therapeutic index.
• Excipients commonly used in IR solid oral dosage forms are unlikely to pose significant risks.

Conclusions:

• A waiver of in vivo bioequivalence testing for IR solid oral dosage forms of prednisolone is likely feasible.
• Formulations containing specific excipients are unlikely to pose undue risks to patients.
• Biowaiver decisions should consider drug properties, pharmacokinetics, and excipient compatibility.